A system for performing a minimally invasive percutaneous procedure comprises a medical device comprising a hydrogel delivery needle (4) with a tip and a hydrogel outlet (6), an injectable, shear-thinning, self-healing viscoelastic hydrogel that exhibits a storage modulus (G) of at least 600 Pa, and a tan (G/G) from 0.1 to 0.6 in dynamic viscoelasticity measured by a rheometer at 1 Hz and 1% strain rate at 25 C. The system may also comprise a coaxial cannula (2) having a lumen configured for receipt of the hydrogel delivery needle (4), wherein the hydrogel delivery needle comprises an adjustable positioning mechanism (8) configured to limit the advancement depth of the hydrogel delivery needle through the coaxial cannula to a predetermined depth distal to a distal-most end of the coaxial cannula.

An adhesive composition is intended to provide the attaching to human skin, comprising a continuous phase and a discontinuous phase of hydrocolloids, with the continuous phase comprising by weight, based on the total weight of the adhesive composition: (i) 1 to 12% by weight of a sequenced polymer of the styrene-isoprene-styrene or styrene-butadiene-styrene type, (ii) (a) 1 to 15% of a polymer of the elastomer butyl type, possibly as a mixture with up to 25% by weight of a polymer of the polyisobutylene type, or (b) more than 10% to 30% of a polymer of the polyisobutylene type, free of polymer of the elastomer butyl type, (iii) 1 to less than 10% of a polymer of the ethylene vinyl acetate type, with the sum of these three types of polymers representing from 10 to 40%.

An adhesive composition is intended to provide the attaching to human skin, comprising a continuous phase and a discontinuous phase of hydrocolloids, with the continuous phase comprising by weight, based on the total weight of the adhesive composition: (i) 1 to 12% by weight of a sequenced polymer of the styrene-isoprene-styrene or styrene-butadiene-styrene type, (ii) (a) 1 to 15% of a polymer of the elastomer butyl type, possibly as a mixture with up to 25% by weight of a polymer of the polyisobutylene type, or (b) more than 10% to 30% of a polymer of the polyisobutylene type, free of polymer of the elastomer butyl type, (iii) 1 to less than 10% of a polymer of the ethylene vinyl acetate type, with the sum of these three types of polymers representing from 10 to 40%.

Composites, are provided, the composites comprising: mixed conducting particles; and an ion conducting scaffolding matrix. In some embodiments, the mixed conducting particles are made from poly(3,4-ethylenedioxythiophene)-poly(styrenesulfonate). In some embodiments, the ion conducting scaffolding matrix includes a chitosan (CS)-based polymer. In some embodiments, devices are provided, the devices comprising: a composite comprising mixed conducting particles and an ion conducting scaffolding matrix; and three electrodes, wherein: each of the three electrodes is in contact with the composite; a first pair of the three electrodes are on opposite sides of the composite and are a distance h apart; a second pair of the three electrodes are on a same side of the composite and are a distance d1 apart; a particle size of the mixed conducting particles is between h and d1; a mean-free-path of the mixed conducting particles is less than d1; and the composite behaves like an anisotropic conductor.

The present invention provides a bone cement composition kit. The bone cement composition kit includes a bone matrix component and a hydrogel component, respectively stored in separate containers, wherein the bone matrix component includes a bone matrix, the hydrogel component includes an acrylic polymer and an acrylic monomer. A ratio of the bone matrix component to the hydrogel component is in a range from about 1:2 (mL/mL) to about 1:50 (mL/mL).

The present invention is directed to hemostatic sealants having a compressed porous substrate, an electrophilic group containing component that is not gelatin or collagen, a nucleophilic group containing component, and a buffering agent. The present invention also relates to method for manufacture and use of such sealants to seal and/or achieve hemostasis.

A hemostatic composition of matter includes a coherent blend of collagen fibrils combined with starch particles as a fluffy mass with hemostatic properties better than collagen fibrils alone or starch particles alone, the composition exhibiting a level of coherence wherein the composition can be lifted, without crushing fibrils, without loss of more than 5% of 10% of a total weight of starch particles from the composition. Sheets with less than 10% by weight of additional binder are also disclosed.

A hemostatic composition of matter includes a coherent blend of collagen fibrils combined with starch particles as a fluffy mass with hemostatic properties better than collagen fibrils alone or starch particles alone, the composition exhibiting a level of coherence wherein the composition can be lifted, without crushing fibrils, without loss of more than 5% of 10% of a total weight of starch particles from the composition. Sheets with less than 10% by weight of additional binder are also disclosed.

The subject matter of the invention is an autopolymerisable 2-component prosthetic base material, a kit containing the material as well as a method for its production comprising at least one liquid monomer component (A), and at least one powdered component (B), wherein the prosthetic material in component (A) besides methylmethacrylate contains at least one N-alkyl-substituted acryloyloxy carbamate having a molecular mass of less than or equal to 250 g/mol, optionally at least one at least di-functional urethane (meth)acrylate, a di-, tri-, tetra- or multi-functional monomer not being urethane (meth)acrylate, and optionally polymeric particles having a primary particle size of less than 800 nm, and the powdered component (B) comprises polymeric particles having at least three different particle size fractions, and both (A) and (B) contains at least one initiator or at least one component of an initiator system for autopolymerisation.

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I) ##STR00001##
applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.